[go: up one dir, main page]

Wattenberg et al., 1987 - Google Patents

Inhibition of β-propiolactone-induced mutagenesis and neoplasia by sodium thiosulfate

Wattenberg et al., 1987

Document ID
2720210628114669537
Author
Wattenberg L
Hochalter J
Galbraith A
Publication year
Publication venue
Cancer research

External Links

Snippet

Studies have been initiated to find compounds that can trap directacting carcinogens within the stomach. Sodium thiosulfate (STS) is a potent nucleophile and in initial experiments was found to inhibit mutagenesis resulting from exposure of Salmonella typhimurium strain …
Continue reading at aacrjournals.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Gurtoo et al. Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide
Mudge et al. Effect of 2, 4-dinitrophenol on renal transport mechanisms in the dog
Oliverio et al. The absorption, distribution, excretion, and biotransformation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in animals
Skipper et al. Observations on inhibition of nucleic acid synthesis resulting from administration of nitrogen mustard, urethan, colchicine, 2, 6-diaminopurine, 8-azaguanine, potassium arsenite, and cortisone
Weissbach et al. In vivo metabolism of serotonin and tryptamine: effect of monoamine oxidase inhibition
Wattenberg et al. Inhibition of β-propiolactone-induced mutagenesis and neoplasia by sodium thiosulfate
TW422685B (en) A pharmaceutical composition for treating viral infections and cancers or tumors
Barron et al. Reactivation by dithiols of enzymes inhibited by lewisite
CA2260266C (en) Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Craddock Stability of deoxyribonucleic acid methylated in the intact animal by administration of dimethylnitrosamine. Rate of breakdown in vivo and in vitro at different dosages
Svensson et al. Kinetics of metabolism of propene and covalent binding to macromolecules in the mouse
EP2116241A1 (en) Pharmaceutical composition
Dixon Effect of chloramphenicol on the metabolism and lethality of cyclophosphamide in rats
Fasth et al. Protective effect of thiosulfate and metabolic thiosulfate precursors against toxicity of nitrogen mustard (HN2)
Buzzi et al. Inhibition of growth of Ehrlich tumors in Swiss mice by diphtheria toxin
Ray et al. Pharmacokinetics of the anti-AIDS drug 2', 3'-dideoxyinosine in the rat.
Bergman et al. Methylation of rat and mouse DNA by the mushroom poison gyromitrin and its metabolite monomethylhydrazine
Rogers et al. The fate of 5-trifluoromethyl-2′-deoxyuridine in monkeys, dogs, mice, and tumor-bearing mice
Alexander et al. Inhibition of Aminonucleoside Nephrosis in Rats: I. The Effect of Adenine, Adenosine and Adenosine Triphosphate
US5288718A (en) Method for decorporating radioactive isotope from living organism
Pfeffer et al. Human urinary excretion of the quaternary ammonium compounds anisotropine methylbromide and propantheline bromide
Rao et al. Studies on the origin of the hyperglycaemic glycogenolytic factor (HGF)
Smith et al. The pharmacologic and chemotherapeutic action of some new sulfones and streptomycin in experimental tuberculosis
Kadar et al. Isoproterenol metabolism in children after intravenous administration
Allan et al. The metabolic and pharmacokinetic disposition of mebendazole in the rat